The Prognostic Value of Lung Injury and Fibrosis Markers, KL-6, TGF-β1, FGF-2 in COVID-19 Patients.
Coronavirus disease 2019
Krebs von den Lungen-6
biomarker
computed tomography
fibroblast growth factor-2
transforming growth factor-beta1
Journal
Biomarker insights
ISSN: 1177-2719
Titre abrégé: Biomark Insights
Pays: United States
ID NLM: 101288638
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
07
2022
accepted:
11
10
2022
entrez:
16
11
2022
pubmed:
17
11
2022
medline:
17
11
2022
Statut:
epublish
Résumé
Biomarkers of lung injury and interstitial fibrosis give insight about the extent of involvement and prognosis in well-known interstitial lung diseases (ILD). Serum Krebs von den Lungen-6 (KL-6) reflects direct alveolar injury and, transforming growth factor-beta1 (TGF-β1) and fibroblast growth factor-2 (FGF-2) are principal mediators of fibrosis in ILD and in almost all fibrotic diseases. In this sense, we aimed to assess associations of these biomarkers with traditional inflammatory markers and clinical course of COVID-19. Patients with COVID-19 who had confirmed diagnosis with SARS-CoV-2 nucleic acid RT-PCR were enrolled and followed up prospectively with a standardized approach one month after diagnosis. Patients were divided into severe and non-severe groups according to National Institutes of Health criteria. Outcome was assessed for the requirement of intensive care unit (ICU) admission, long term respiratory support and death. Blood samples were collected at enrollment and serum levels of KL-6, TGF-β1, FGF-2 were determined by ELISA. Association between these markers with other prognostic markers and prognosis were analyzed. Overall 31 severe and 28 non-severe COVID-19 patients were enrolled and were compared with healthy control subjects (n = 30). Serum KL-6 levels in COVID-19 patients were significantly higher (median [IQR]; 11.54 [4.86] vs 8.54 [3.98] ng/mL, Serum KL-6 levels were significantly elevated at the diagnosis of COVID-19 and correlated well with the other traditional prognostic inflammatory markers. Serum levels of principal fibrosis mediators, TGF-β1, FGF-2, were not elevated at diagnosis of COVID-19, therefore did not help to anticipate long term prognosis.
Sections du résumé
Background
UNASSIGNED
Biomarkers of lung injury and interstitial fibrosis give insight about the extent of involvement and prognosis in well-known interstitial lung diseases (ILD). Serum Krebs von den Lungen-6 (KL-6) reflects direct alveolar injury and, transforming growth factor-beta1 (TGF-β1) and fibroblast growth factor-2 (FGF-2) are principal mediators of fibrosis in ILD and in almost all fibrotic diseases. In this sense, we aimed to assess associations of these biomarkers with traditional inflammatory markers and clinical course of COVID-19.
Methods
UNASSIGNED
Patients with COVID-19 who had confirmed diagnosis with SARS-CoV-2 nucleic acid RT-PCR were enrolled and followed up prospectively with a standardized approach one month after diagnosis. Patients were divided into severe and non-severe groups according to National Institutes of Health criteria. Outcome was assessed for the requirement of intensive care unit (ICU) admission, long term respiratory support and death. Blood samples were collected at enrollment and serum levels of KL-6, TGF-β1, FGF-2 were determined by ELISA. Association between these markers with other prognostic markers and prognosis were analyzed.
Results
UNASSIGNED
Overall 31 severe and 28 non-severe COVID-19 patients were enrolled and were compared with healthy control subjects (n = 30). Serum KL-6 levels in COVID-19 patients were significantly higher (median [IQR]; 11.54 [4.86] vs 8.54 [3.98] ng/mL,
Conclusions
UNASSIGNED
Serum KL-6 levels were significantly elevated at the diagnosis of COVID-19 and correlated well with the other traditional prognostic inflammatory markers. Serum levels of principal fibrosis mediators, TGF-β1, FGF-2, were not elevated at diagnosis of COVID-19, therefore did not help to anticipate long term prognosis.
Identifiants
pubmed: 36380740
doi: 10.1177/11772719221135443
pii: 10.1177_11772719221135443
pmc: PMC9643117
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11772719221135443Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Mucosal Immunol. 2009 Mar;2(2):103-21
pubmed: 19129758
J Leukoc Biol. 2021 Jan;109(1):55-66
pubmed: 32930456
Lancet. 2020 Mar 7;395(10226):809-815
pubmed: 32151335
PLoS One. 2021 Apr 29;16(4):e0249607
pubmed: 33914762
Int J Biol Sci. 2021 Apr 10;17(6):1565-1573
pubmed: 33907520
J Intern Med. 2006 Nov;260(5):429-34
pubmed: 17040248
Ann Intensive Care. 2020 Mar 18;10(1):33
pubmed: 32189136
Respir Investig. 2021 Sep;59(5):596-601
pubmed: 33965361
J Immunol. 2004 Aug 1;173(3):2099-108
pubmed: 15265946
Elife. 2022 Jan 13;11:
pubmed: 35023830
Nat Commun. 2021 Mar 30;12(1):1961
pubmed: 33785765
Biomedicines. 2021 Dec 17;9(12):
pubmed: 34944747
Int J Mol Sci. 2021 Dec 24;23(1):
pubmed: 35008594
Front Biosci (Landmark Ed). 2012 Jun 01;17(7):2667-74
pubmed: 22652804
FEBS Lett. 2021 Jul;595(13):1819-1824
pubmed: 33961290
Lancet Infect Dis. 2020 Jul;20(7):776-777
pubmed: 32224313
Respir Res. 2020 Nov 24;21(1):309
pubmed: 33234132
Postgrad Med J. 2020 Jul;96(1137):403-407
pubmed: 32522846
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
J Cell Mol Med. 2016 Nov;20(11):2183-2193
pubmed: 27420297
N Engl J Med. 2020 Feb 27;382(9):872-874
pubmed: 31991079
J Med Virol. 2020 Oct;92(10):2216-2220
pubmed: 32470148
Front Pharmacol. 2022 Jan 05;12:805535
pubmed: 35069217
J Biol Chem. 2005 Dec 30;280(52):43000-9
pubmed: 16246848
Endocr Rev. 1994 Feb;15(1):27-39
pubmed: 8156937
Turk J Med Sci. 2021 Nov 30;51(SI-1):3391-3404
pubmed: 34844296
Eur Respir J. 2004 Jan;23(1):142-5
pubmed: 14738246
Front Pharmacol. 2022 Mar 04;13:748931
pubmed: 35308222
Am J Pathol. 2022 Jul;192(7):990-1000
pubmed: 35483427
Am J Pathol. 2005 May;166(5):1321-32
pubmed: 15855634
Chest. 1989 Jul;96(1):68-73
pubmed: 2661160
Exp Mol Pathol. 2016 Aug;101(1):22-30
pubmed: 27112840